This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the effectiveness and toxicity profile of erlotinib alone or combined with other therapies for the treatment of advanced pancreatic cancer, as first-line, second-line or palliative treatment.
Erlotinib for advanced pancreatic cancer / Baldo, P.; Giacomin, E.; Cecco, S.; D'Amico, R.; Cannizzaro, R.; Balduzzi, S.. - In: COCHRANE DATABASE OF SYSTEMATIC REVIEWS. - ISSN 1469-493X. - 2015:1(2015), pp. 1-11. [10.1002/14651858.CD011463]
Erlotinib for advanced pancreatic cancer
D'Amico R.;Balduzzi S.
2015
Abstract
This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the effectiveness and toxicity profile of erlotinib alone or combined with other therapies for the treatment of advanced pancreatic cancer, as first-line, second-line or palliative treatment.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Baldo_et_al-2015-Cochrane_Database_of_Systematic_Reviews.pdf
Accesso riservato
Tipologia:
AO - Versione originale dell'autore proposta per la pubblicazione
Dimensione
269.15 kB
Formato
Adobe PDF
|
269.15 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
